Matches in SemOpenAlex for { <https://semopenalex.org/work/W2726993857> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2726993857 endingPage "93" @default.
- W2726993857 startingPage "87" @default.
- W2726993857 abstract "Purpose. To investigate the efficacy of recombinant prourokinase (RPU) treatment in patients with toxic anterior segment syndrome after phacoemulsification.
 Material and methods. We observed 123 patients (123 eyes) with toxic anterior segment syndrome after phacoemulsification; patients of the group I (n = 30) received only antiinflammatory treatment; in treatment of patients of the group II (n = 31), instillations of the RPU solution were used, in the group III (n = 31), RPU solution was injected subconjunctivally, in the group IV (n = 31) RPU solution electrophoresis was used. Treatment result analysis was carried out within 30 days.
 Results. Initial mean visual acuity in groups was 0.09 0.04; 0.1 0.04; 0.09 0.04; 0.08 0.04, and was virtually the same (p 0.05). In 24 hours after treatment initiation, mean visual acuity in the group III was higher, than in the others. In three days and up to the end of observation period, the lowest mean visual acuity was noted in the group I (p 0.05). Anterior chamber assessment showed that beginning from the first 24 hours after treatment initiation, in groups III and IV, fibrin lysis in the anterior chamber was more pronounced, than in groups I and II (p 0.05); by the end of the observation period, worst indices of anterior chamber state were found in the group I (p 0.05), in other groups, they were almost identical (p 0.05). When using RPU, no allergic reaction was noted.
 Conclusions. RPU use in combined toxic anterior segment syndrome therapy after phacoemulsification allows increasing visual acuity, reducing convalescence time, and reducing the number of laser dissections. It was established that all methods of RPU administration are effective. RPU may be administered as eye drops on an outpatient basis, receiving efficacy similar to other administration methods." @default.
- W2726993857 created "2017-07-14" @default.
- W2726993857 creator A5003585106 @default.
- W2726993857 creator A5013457143 @default.
- W2726993857 creator A5036170844 @default.
- W2726993857 creator A5054990634 @default.
- W2726993857 date "2017-05-15" @default.
- W2726993857 modified "2023-09-26" @default.
- W2726993857 title "Enzymotherapy of toxic anterior segment syndrome after phacoemulsification" @default.
- W2726993857 cites W1982615174 @default.
- W2726993857 cites W1987099540 @default.
- W2726993857 cites W1988890047 @default.
- W2726993857 cites W2016681282 @default.
- W2726993857 cites W2026593223 @default.
- W2726993857 cites W2036667265 @default.
- W2726993857 cites W2083553624 @default.
- W2726993857 cites W2129262684 @default.
- W2726993857 doi "https://doi.org/10.17816/ov10287-93" @default.
- W2726993857 hasPublicationYear "2017" @default.
- W2726993857 type Work @default.
- W2726993857 sameAs 2726993857 @default.
- W2726993857 citedByCount "3" @default.
- W2726993857 countsByYear W27269938572020 @default.
- W2726993857 countsByYear W27269938572022 @default.
- W2726993857 countsByYear W27269938572023 @default.
- W2726993857 crossrefType "journal-article" @default.
- W2726993857 hasAuthorship W2726993857A5003585106 @default.
- W2726993857 hasAuthorship W2726993857A5013457143 @default.
- W2726993857 hasAuthorship W2726993857A5036170844 @default.
- W2726993857 hasAuthorship W2726993857A5054990634 @default.
- W2726993857 hasBestOaLocation W27269938571 @default.
- W2726993857 hasConcept C118487528 @default.
- W2726993857 hasConcept C141071460 @default.
- W2726993857 hasConcept C2778257484 @default.
- W2726993857 hasConcept C2781104129 @default.
- W2726993857 hasConcept C71924100 @default.
- W2726993857 hasConceptScore W2726993857C118487528 @default.
- W2726993857 hasConceptScore W2726993857C141071460 @default.
- W2726993857 hasConceptScore W2726993857C2778257484 @default.
- W2726993857 hasConceptScore W2726993857C2781104129 @default.
- W2726993857 hasConceptScore W2726993857C71924100 @default.
- W2726993857 hasIssue "2" @default.
- W2726993857 hasLocation W27269938571 @default.
- W2726993857 hasOpenAccess W2726993857 @default.
- W2726993857 hasPrimaryLocation W27269938571 @default.
- W2726993857 hasRelatedWork W2045379344 @default.
- W2726993857 hasRelatedWork W2347521380 @default.
- W2726993857 hasRelatedWork W2350393446 @default.
- W2726993857 hasRelatedWork W2359106421 @default.
- W2726993857 hasRelatedWork W2365740287 @default.
- W2726993857 hasRelatedWork W2368847723 @default.
- W2726993857 hasRelatedWork W3029446580 @default.
- W2726993857 hasRelatedWork W3031887308 @default.
- W2726993857 hasRelatedWork W3156169496 @default.
- W2726993857 hasRelatedWork W4210673973 @default.
- W2726993857 hasVolume "10" @default.
- W2726993857 isParatext "false" @default.
- W2726993857 isRetracted "false" @default.
- W2726993857 magId "2726993857" @default.
- W2726993857 workType "article" @default.